The Best Hearing Aids I’ve Tested (2026): Jabra, Resound, Apple, and More

The review ranks the Jabra Enhance Select 300 as its best hearing aid, with prices spanning from $100 for JLab Hear to $4,000 for Starkey Edge AI RIC RT; prescription models generally cost $2,000–$8,000, while highly rated OTC pairs typically cost $800–$2,000. The article says FDA approval of OTC hearing aids in 2022 expanded consumer options, but warns that many low-cost devices are ineffective and that poor hearing aids can harm hearing. It recommends professional testing for diagnosis and emphasizes that device quality, fitting, support, and coverage vary.

Analysis

The investable signal is channel pressure, not evidence of a near-term earnings inflection. Consumer devices can lower the stigma and trial cost of hearing support, potentially expanding adoption; the countervailing effect is price anchoring that makes traditional prescription aids harder to justify at the entry level. That should favor companies able to defend value through fitting, ongoing audiology support, and performance in more complex hearing loss, while exposing undifferentiated low-end devices. Apple’s AirPods are better viewed as an on-ramp than a broad substitute for prescription products; the article itself limits the comparison to mild-to-moderate needs. GN has exposure on both sides through Jabra OTC and ReSound prescription products, but one favorable product review is not evidence of material share gains. Sony’s review is similarly a product signal, not a sales datapoint.

Near term, this is low-impact editorial coverage; avoid trading the names on it alone. Over 1–3 months, monitor company commentary and reported growth, pricing, and channel data for OTC hearing products. Over 6–18 months, the key question is whether simpler consumer devices expand the category or mainly divert buyers from incumbent entry-level products. The contrarian point: broader access may enlarge the funnel for professional care rather than eliminate it, since self-fitting products do not resolve every hearing condition. A shift toward substitution would be more credible if OTC growth coincides with weaker prescription volumes or pricing. The thesis weakens if OTC adoption remains niche or if service-led prescription demand holds up.

Key Decisions for Investors

• No immediate position based on this article. Its rankings are qualitative product testing, not independently verified sales, market-share, or margin evidence.
• Track GN for a possible two-sided outcome: Jabra could benefit from OTC adoption while ReSound may face entry-level price pressure. Revisit only with segment-level growth, pricing, or guidance evidence; do not infer consolidated impact from the review.
• Treat AAPL and SONY as watch items, not hearing-aid earnings trades: verify management commentary or disclosed adoption indicators before attributing meaningful financial impact to these products.
• Falsification/watch trigger: evidence over the next 1–3 months that OTC unit growth is accompanied by sustained prescription-volume or pricing deterioration would strengthen the substitution risk; resilient prescription demand alongside category growth would favor the market-expansion interpretation.